Inventiva SA’s stock (IVA) soared over 30% on Monday after the company announced securing significant financing for its NASH drug, lanifibranor. This funding will fuel the completion of the Phase 3 NATiV3 MASH trial and potential marketing approval, boosting investor confidence.